Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis

Jundishapur Journal of Microbiology

Volumn 3, Issue 2, 2010, Pages 79-83

  Mapar, Mohammad Ali ^a   Omidian, Mohammad ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Glucantim; Meglumine antimoniate; Metronidazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; MEGLUMINE ANTIMONATE; METRONIDAZOLE; UREA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; EDEMA; FEMALE; HUMAN; INFLAMMATION; INJECTION SITE PAIN; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; SKIN LEISHMANIASIS; UREA NITROGEN BLOOD LEVEL;

EID: 77954918326     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. WHO: Cutaneous leishmaniasis. Informal Consultative Meeting for the Control of Cutaneous Leishmaniasis in the Middle East and Maghreb, Geneva, on 30 April-2 May 2007.
2. Rastogi V, Nirwan PS. Cutaneous leishmaniasis: An emerging infection in a non-endemic area and a brief update. Indian J Med Microbiol. 2007; 25: 272-5.
3. Long PI. Cutaneous leishmaniasis treated with metronidazole. JAMA. 1973; 223: 1378-9.
4. Pedersen JK, Sawicki S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol. 1975; 111: 1343-4.
5. Beltran F, Gutierrrez M, Biagi F: Utilite du metronidazole dans le traitement de la leishmaniose cutanee Mexicaine. Bull Soc Pathol Exot.1967; 50: 61-4.
6. Griffiths WAD, Sodeify M. Use of metronidazole in cutaneous leishmaniasis. Arch Dermatol. 1976; 112: 1791.
7. Asher W, Chaim C. Cutaneous leishmaniasis: In efficacity of treatment with metronidazole. Arch Dermatol. 1977; 113: 1299.
8. Walton BC, Paulson JB, Aryona MA, Peterson CA. American cutaneous leishmaniasis, inefficacy of metronidazole in treatment. JAMA. 1974; 228: 1256-8.
9. Kashani MN, Firooz A, Eskandari SE, et al. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol. 2007; 17: 513-5.
10. Radmanesh M, Falahzadeh A, Dowraghi HF. Weekly versus every 3 days intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. J Dermatol Treat. 1998; 9: 231-3.
11. Bogenrieder T, Lehn N, Landthaler M, Stolz W. Treatment of old world cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Dermatology. 2003; 206: 269-72.
12. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol. 2003; 97: 493-8.
13. Aronson NE, Wortmann GW, Johnson SC. et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis. 1998; 27: 1457-64.
14. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006; 3(5): e162.
15. Molavi A, LeFrock JL, Prince RA. Metronidazole. Med Clin North Am. 1982; 66: 121-33.
16. Al-Waiz M, Sharquie KE, Al-Assir M. Treatment of cutaneous leishmaniasis by intralesional metronidazole. Saudi Med J. 2004; 25(10): 1512-3.